Trial Profile
An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Adverse reactions; Registrational
- Sponsors Amgen
- 01 Jun 2020 Results of integrated analysis of five clinical trials evaluating the efficacy and safety of romiplostim self-administration published in the American Journal of Hematology
- 06 Nov 2017 New trial record